Luke Evnin Sells 29,595 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 29,595 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $0.45, for a total transaction of $13,317.75. Following the sale, the director owned 512,525 shares of the company’s stock, valued at approximately $230,636.25. This represents a 5.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $12,494.58.
• On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total transaction of $37,815.73.
• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $14,650.20.
• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.46, for a total transaction of $12,741.08.
• On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.48, for a total transaction of $38,808.96.
• On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $31,936.50.
• On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $39,341.25.
• On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $15,282.54.
• On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.43, for a total transaction of $36,934.85.
• On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $28,336.50.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $0.43 on Friday. The firm’s 50-day simple moving average is $0.71 and its 200-day simple moving average is $0.73. Werewolf Therapeutics, Inc. has a twelve month low of $0.40 and a twelve month high of $2.38. The firm has a market cap of $20.90 million, a P/E ratio of -0.35 and a beta of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. On average, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on HOWL shares. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $3.75.

Institutional Trading of Werewolf Therapeutics

Several hedge funds have recently bought and sold shares of HOWL. Regal Investment Advisors LLC raised its holdings in Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after buying an additional 25,389 shares during the period. Vontobel Holding Ltd. raised its holdings in Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares during the period. Qube Research & Technologies Ltd acquired a new stake in Werewolf Therapeutics during the 2nd quarter worth approximately $48,000. AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics during the 1st quarter worth approximately $79,000. Finally, Bridgeway Capital Management LLC raised its holdings in Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after buying an additional 62,414 shares during the period. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.